高级检索
当前位置: 首页 > 详情页

Structural characteristics of Heparan sulfate required for the binding with the virus processing Enzyme Furin.

文献详情

资源类型:
Pubmed体系:
机构: [1]The First Afliated Hospital of Guangzhou University of Chinese Medicine, No. 16 Jichang Road, Guangdong Province 510405 Guangzhou, China [2]Carbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 200031, China [3]Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China [4]School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China [5]Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida Health, Tampa, FL, USA
出处:
ISSN:

关键词: Furin Heparan sulfate Heparin Virus infection Carbohydrate-protein interaction

摘要:
Furin is one of the nine-member proprotein convertase family. Furin cleaves proteins with polybasic residues, which includes many viral glycoproteins such as SARS-Cov-2 spike protein. The cleavage is required for the activation of the proteins. Currently, the mechanisms that regulate Furin activity remain largely unknown. Here we demonstrated that Furin is a novel heparin/heparan sulfate binding protein by the use of biochemical and genetic assays. The KD is 9.78 nM based on the biolayer interferometry assay. Moreover, we found that sulfation degree, site-specific sulfation (N-sulfation and 3-O-sulfation), and iduronic acid are the major structural determinants for the binding. Furthermore, we found that heparin inhibits the enzymatic activity of Furin when pre-mixes heparin with either Furin or Furin substrate. We also found that the Furin binds with cells of different origin and the binding with the cells of lung origin is the strongest one. These data could advance our understanding of the working mechanism of Furin and will benefit the Furin based drug discovery such as inhibitors targeting the interaction between heparan sulfate and Furin for inhibition of viral infection.© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 生物
小类 | 4 区 生化与分子生物学
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 生化与分子生物学
第一作者:
第一作者机构: [1]The First Afliated Hospital of Guangzhou University of Chinese Medicine, No. 16 Jichang Road, Guangdong Province 510405 Guangzhou, China [2]Carbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 200031, China [4]School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
通讯作者:
通讯机构: [2]Carbohydrate-Based Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 200031, China [3]Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China [4]School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号